Home > Press > Audax Medical, Inc. Secures Exclusive Rights to Novel Osteobiologic Nanotechnology
Abstract:
Audax Medical, Inc., a privately-held medical device company specializing in the development of osteobiologics, has entered into a comprehensive license agreement with Brown University, acquiring exclusive rights to a proprietary osteobiologic nanotechnology.
The biomaterial, Arxis™, is being developed for use in multiple clinical applications for the regeneration of diseased bone, cartilage, and other soft tissues.
An additional research agreement has been completed with the Brown University School of Engineering and Department of Orthopedics to further support clinical development of the technology.
"Our partnership with Brown and the University's world-class scientific team is a significant milestone for Audax Medical," stated Mark A. Johanson, President and Chief Executive Officer. "The addition of this technology to the company's product portfolio greatly expands our growing regenerative osteobiologics and soft tissue platforms."
Under the terms of the agreement, Audax Medical has obtained exclusive license to a platform of intellectual property and technologies co-developed by Thomas Webster, Brown professor of engineering, addressing the treatment of degenerative bone and soft tissues.
"We are very excited to have partnered with such an experienced and accomplished team at Audax Medical," stated Katherine Gordon, Managing Director of the Brown University Technology Ventures Office. "The scientific and commercial expertise from both the Brown and Audax teams are impressive, offering a significant opportunity for both clinical and commercial success."
The Arxis™ biomaterial consists of organic nanomolecules which have the potential to meet an array of clinical needs. The implantable material can incorporate varying growth agents that allow its end characteristics to be customized for multiple clinical and regenerative indications throughout the musculoskeletal system.
More information about the science behind the technology, including pictures and video, can be found at today.brown.edu/articles/2010/11/audax.
####
About Audax Medical
Audax Medical, Inc. is a privately held medical device company located in Littleton, Massachusetts. The company offers innovative solutions for the treatment of degenerative bone and musculoskeletal tissue. The company's products go beyond simply stabilizing a clinical deficiency by promoting the growth of natural bone and tissue. With enhanced surgical based solutions and osteogenic biomaterial technologies, Audax offers a modern alternative to existing orthopedic therapies.
For more information, please click here
Contacts:
978.952.2522
Copyright © Audax Medical
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||